文献速递临床试验与 GCP

松龄血脉康胶囊治疗低中危高血压患者:随机对照试验研究方案

Songling Xuemaikang capsules for patients with low-to-medium risk hypertension: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-04-15

本研究为多中心、安慰剂对照、双盲随机对照试验,计划纳入570例低中危高血压患者,按1:1比例随机接受松龄血脉康胶囊或安慰剂每日三次、治疗八周,主要结局为24小时平均收缩压和平均舒张压,旨在评估单用松龄血脉康胶囊治疗高血压的疗效与安全性。

要点

  • 松龄血脉康胶囊自1994年起在中国大陆作为中成药与常规西药联合用于高血压的补充治疗。
  • 本试验为多中心、安慰剂对照、双盲随机对照试验,纳入570例低中危高血压患者。
  • 患者按1:1随机接受松龄血脉康胶囊或安慰剂每日三次、治疗八周,主要结局为24小时平均收缩压和平均舒张压。

核心结论

  • 单用松龄血脉康胶囊治疗高血压的疗效尚不明确,本试验旨在评估其疗效与安全性。
  • 本研究将为高血压的补充预防措施提供循证依据。

研究设计与样本

  • 多中心、安慰剂对照、双盲随机对照临床试验。
  • 共纳入570例低中危高血压患者,按1:1比例随机接受松龄血脉康胶囊或安慰剂每日三次、治疗八周。
  • 主要结局为24小时平均收缩压和平均舒张压。
  • 次要结局为日间平均血压、夜间平均血压、血压波动、高血压控制率、中医证候评分和生活质量评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is a major risk factor for cardio-cerebrovascular disease. Songling Xuemaikang capsules (SXC), a formulation of Chinese herbal patent medicine, has been used as a complementary medicine with conventional western medicine to treat patients with hypertension since 1994 in mainland China. However, the efficacy of treatment with SXC alone against hypertension remains unclear. METHODS/DESIGN: This is a multicenter, placebo-controlled, double-blinded, randomized controlled clinical trial. A total of 570 patients with low-to-medium risk hypertension are randomized in a 1:1 ratio to receive SXC or placebo three times daily for eight weeks. The primary outcomes are 24-h average systolic blood pressure and average diastolic blood pressure. The secondary outcomes are daytime average blood pressure, night-time average blood pressure, fluctuation of blood pressure, hypertension control rate, traditional Chinese medicine (TCM) syndrome scores, and quality-of-life scores. DISCUSSION: This is the first multicenter trial conducted to evaluate the efficacy and safety of TCM in patients with low-to-medium risk hypertension. Our study will provide evidence-based results of a complementary preventive measure for hypertension. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IPR-17011383 . Registered on 12 May 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Guo H, Liu Y, et al. Songling Xuemaikang capsules for patients with low-to-medium risk hypertension: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30987658. doi:10.1186/s13063-019-3308-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。